Company Profile
| Company Name | LibraMedicina, Inc. |
| Chief Executive Officer & President | Keizo Hanada |
| Head Office |
Nihonbashi Life Science Bld2, Room 704, 3-11-5, Nihonbashi-honcho, Chuo-ku, Tokyo, 103-0023, Japan |
| Date Established | May, 2009 |
| Capital | 60 million yen (including capital reserve) |
| Business Fields | 1. Biopharmacy R & D and manufacturing contract intermediary service |
| 2. Intermediary service for contract research and development and manufacturing of synthetic drugs | |
| 3. Consulting for the development of pharmaceuticals, medical devices, and functional products | |
| 4. Intermediary service for contract manufacturing of functional products, etc. | |
| 5. Licensing (pharmaceutical products, medical devices, functional products) | |
| Major Shareholders | ・ Social Impact Solutions Co., Ltd. |
| ・ Yamasa Corporation | |
| ・ Japan Strategic Capital Co., Ltd. | |
| Number of Staff | 10 people including board members |
|
- Ph.D. in Pharmacy, Veterinary, Medical, and Science - Master of Systems engineering, Master of Science - Qualified Veterinarian External consultants in pharmaceuticals under a non-disclosure agreement |
|
| Major business partners |
・ Pharmaceutical companies listed on the First Section of the Tokyo Stock Exchange and Mothers. ・Chemical manufacturing industries ・ Food and enzyme industries ・ Bio-venture, drug discovery startup companies ・ Other diverse industries |
